Drug profile · INN
vutrisiran sodium
AMVUTTRA
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
vutrisiran sodium (AMVUTTRA) is an FDA-listed pharmaceutical active ingredient. Associated with Alnylam Netherlands B.V.. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
INN vutrisiran sodium
Brand AMVUTTRA
Route SUBCUTANEOUS
Formulation SOLUTION
Originator Alnylam Netherlands B.V.
Frequently asked questions
What is vutrisiran sodium?
vutrisiran sodium (AMVUTTRA) is an FDA-listed pharmaceutical active ingredient. Associated with Alnylam Netherlands B.V.. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for vutrisiran sodium?
AMVUTTRA is a marketed brand name for vutrisiran sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of vutrisiran sodium?
vutrisiran sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.